Insulin resistance and heart failure

Current Heart Failure Reports

Volumn 6, Issue 2, 2009, Pages 89-94

  Heck, Patrick M ^a   Dutka, David P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; ETOMOXIR; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; METFORMIN; METOPROLOL; NITRIC OXIDE; PERHEXILINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RANOLAZINE; TRIMETAZIDINE;

ANGINA PECTORIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; EDEMA; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FLUID RETENTION; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HEART FAILURE; HEART FUNCTION; HORMONE ACTION; HUMAN; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; MYOCARDIAL DISEASE; NEUROTOXICITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT; SYMPATHETIC TONE; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; INSULIN RESISTANCE; OBESITY; PREVALENCE;

EID: 66749144097     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-009-0014-8     Document Type: Review

References (55)

1. Ioannou GN, Bryson CL, Boyko EJ: Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. J Diabetes Complications 2007, 21: 363-370.
2. Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002, 106: 3068-3072.
3. Leyden D: Asthma und diabetes mellitus. Zeitschr Klin Med 1881, 3: 358-364.
4. Goulston A: A note on the beneficial effect of the ingestion of cane sugar in certain forms of heart disease. Br J Med 1911, 1: 615.
5. Cohen-Solal A, Beauvais F, Logeart D: Heart failure and diabetes mellitus: Epidemiology and management of an alarming association. J Card Fail 2008, 14: 615-625.
6. Swan JW, Anker SD, Walton C, et al.: Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure. J Am Coll Cardiol 1997, 30: 527-532.
7. Nikolaidis LA, Sturzu A, Stolarski C, et al.: The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004, 61: 297-306.
8. MacDonald MR, Petrie MC, Hawkins NM, et al.: Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008, 29: 1224-1240.
9. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974, 34: 29-34.
10. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000, 321: 405-412.
11. Ingelsson E, Sundstrom J, Arnlov J, et al.: Insulin resistance and risk of congestive heart failure. JAMA 2005, 294: 334-341.
12. FerNannini E, Galvan AQ, Gastaldelli A, et al.: Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999, 29: 842-852.
13. Gibbs CL: Cardiac energetics. Physiol Rev 1978, 58: 174-254.
14. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85: 1093-1129.
15. Opie LH: The Heart: Physiology and Metabolism, edn 2. New York: Raven Press; 1991.
16. Opie LH: The metabolic vicious cycle in heart failure. Lancet 2004, 364: 1733-1734.
17. Pessin JE, Thurmond DC, Elmendorf JS, et al.: Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location! J Biol Chem 1999, 274: 2593-2596.
18. Rider MH, Hue L: Activation of rat heart phosphofructokinase-2 by insulin in vivo. FEBS Lett 1984, 176: 484-488.
19. Gamble J, Lopaschuk GD: Insulin inhibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism 1997, 46: 1270-1274.
20. BeutlMr B, Cerami A: Cachectin: more than a tumor necrosis factor. N Engl J Med 1987, 316: 379-385.
21. How OJ, Aasum E, Severson DL, et al.: Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006, 55: 466-473.
22. Iozzo P, Chareonthaitawee P, Dutka D, et al.: Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002, 51: 3020-3024.
23. Doehner W, von Haehling S, Anker SD: Insulin resistance in chronic heart failure. J Am Coll Cardiol 2008, 52: 239.
24. Tuunanen H, Engblom E, Naum A, et al.: Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006, 114: 2130-2137.
25. Raher MJ, Thibault HB, Buys ES, et al.: A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol Heart Circ Physiol 2008, 295: H2459-H2502.
26. Amato L, Paolisso G, Cacciatore F, et al.: Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997, 23: 213-218.
27. Tenenbaum A, Motro M, Fisman EZ, et al.: Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 2003, 114: 271-275.
28. Coats AJ, Anker SD: Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 2000, 35(7 Suppl 4): S9-S14. [Published erratum appears in J Cardiovasc Pharmacol 2001, 38:490.]
29. Opie LH, Thandroyen FT, Muller C, Bricknell OL: Adrenaline-induced "oxygen-wastage" and enzyme release from working rat heart. Effects of calcium antagonism, beta-blockade, nicotinic acid and coronary artery ligation. J Mol Cell Cardiol 1979, 11: 1073-1094.
30. Paolisso G, De Riu S, Marrazzo G, et al.: Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991, 40: 972-977.
31. Paolisso G, Manzella D, Rizzo MR, et al.: Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr 2000, 72: 723-730.
32. Roden M: How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol Sci 2004, 19: 92-96.
33. Marangou AG, Alford FP, Ward G, et al.: Hormonal effects of norepinephrine on acute glucose disposal in humans: A minimal model analysis. Metabolism 1988, 37: 885-891.
34. Nonogaki K: New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000, 43: 533-549.
35. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346: 393-403.
36. Leichman JG, Wilson EB, Scarborough T, et al.: Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery. Am J Med 2008, 121: 966-973.
37. Andraws R, Brown DL: Effect of inhibition of the reninangiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007, 99: 1006-1012.
38. Al-Hesayen A, Azevedo ER, Floras JS, et al.: Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail 2005, 7: 618-623.
39. Kovacic D, Marinsek M, Gobec L, et al.: Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008, 97: 24-31.
40. Alan S, Ulgen MS, Dedeoglu I, et al.: Long-term glucose insulin potassium infusion improves systolic and diastolic function in patients with chronic ischemic cardiomyopathy. Swiss Med Wkly 2003, 133: 419-422.
41. Eurich DT, Majumdar SR, McAlister FA, et al.: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28: 2345-2351.
42. Eurich DT, McAlister FA, Blackburn DF, et al.: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335: 497.
43. Nissen SE, Nicholls SJ, Wolski K, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008, 299: 1561-1573.
44. Guan Y, Hao C, Cha DR, et al.: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11: 861-866.
45. Zanchi A, Chiolero A, Maillard M, et al.: Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004, 89: 1140-1145.
46. Sokos GG, Nikolaidis LA, Mankad S, et al.: Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12: 694-699.
47. Nystrom T: The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 2008, 40: 593-606.
48. Fragasso G, Palloshi A, Puccetti P, et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48: 992-998.
49. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD: Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996, 93: 135-142.
50. Belardinelli L, Shryock JC, Fraser H: Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine. Heart 2006, 92(Suppl 4): Iv6-iv14.
51. Sossalla S, Wagner S, Rasenack EC, et al.: Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008, 45: 32-43.
52. Rastogi S, Sharov VG, Mishra S, et al.: Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008, 295: H2149-H2155.
53. Lee L, Campbell R, Scheuermann-Freestone M, et al.: Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112: 3280-3288.
54. Schmidt-Schweda S, Holubarsch C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000, 99: 27-35.
55. Holubarsch CJ, Rohrbach M, Karrasch M, et al.: A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007, 113: 205-212.